Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Non-Hodgkin Lymphoma | Research

Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020

Authors: Elvynna Leong, Sok King Ong, Khairil Azhar Si-Ramlee, Lin Naing

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

This study presents the trends of age-standardised incidence and mortality rates of common cancers in Brunei Darussalam from 2011 to 2020. All cancer cases diagnosed among Brunei Darussalam citizens and permanent residents in the period 2011 to 2020 were included in the study. De-identified data were provided by the CanReg5 based BDCR, Ministry of Health Brunei Darussalam. The annual age-standardised incidence and mortality rates per 100,000 persons were standardised by the direct method using the World Health Organization (WHO) world standard population distribution. Joinpoint regression analyses were used to study the incidence and mortality trends of cancer in Brunei Darussalam over the 2011–2020 period. Trends were expressed as average annual percent change (AAPC) over 2011 to 2020, or annual percent change (APC) for a given time period. There were a total of 6,495 new cancer cases diagnosed and 3,359 death cases recorded from 2011 to 2020, in Brunei Darussalam. The five common cancers for males were colorectal, lung and bronchus, prostate, liver, and non-Hodgkin lymphoma. Among females, the five most common cancers were breast, colorectal, lung and bronchus, corpus uteri and cervix uteri. The five leading cancer deaths for males were lung and bronchus, colorectal, liver, prostate, and stomach, while for females, the five leading cancer deaths were breast, lung and bronchus, colorectal, ovary, and cervix uteri. There was a significant increase in the incidence trend of corpus uteri (AAPC\(:13.3\)) and a significant decline in the incidence trend for cervical cancer (AAPC\(:-4.5\)) from 2011 to 2020. There was a significant increase in the mortality trend of female breast cancer from 2011 to 2015 (APC\(:16.3\)), but the trend significantly declined from 2015 to 2020 (APC\(:-12.5\)). We also found a significant decrease in mortality trends for stomach cancer (AAPC\(:-4.7\)) from 2011 to 2020 for both genders combined. The burden of common cancers is expected to continue to grow with ageing population, effective public health interventions targeting high burden cancers and high-risk groups, and control of modifiable risk factors will continue to be the essential approaches in reducing cancer burden.
Literature
1.
go back to reference Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years lived with disability, and disability-adjusted life years for 29 Cancer groups from 2010 to 2019: a systematic analysis for the global burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–40.CrossRefPubMed Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years lived with disability, and disability-adjusted life years for 29 Cancer groups from 2010 to 2019: a systematic analysis for the global burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420–40.CrossRefPubMed
2.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
4.
go back to reference Ong SK, Alikhan F, Lai DTC, Abdullah A, Othman K, Naing L. Population Based Lifetime Risk Estimation of Malignant Cancers in Brunei Darussalam. Brunei Int Med J. 2018;14(1):92–101. Ong SK, Alikhan F, Lai DTC, Abdullah A, Othman K, Naing L. Population Based Lifetime Risk Estimation of Malignant Cancers in Brunei Darussalam. Brunei Int Med J. 2018;14(1):92–101.
7.
go back to reference Leong E, Madli F, Ong SK. Five-year survival rate of breast cancer patients in Brunei Darussalam. Brunei Int Med J. 2019;15:73–91. Leong E, Madli F, Ong SK. Five-year survival rate of breast cancer patients in Brunei Darussalam. Brunei Int Med J. 2019;15:73–91.
8.
go back to reference World Health Organization. International statistical classification of diseases and related health problems. 1994. 10th rev. ed. Geneva: World Health Organization. World Health Organization. International statistical classification of diseases and related health problems. 1994. 10th rev. ed. Geneva: World Health Organization.
9.
go back to reference Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: A New WHO standard. Global Programme on Evidence Discussion Paper Series: No. 31. Geneva: World Health Organization; 2001. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: A New WHO standard. Global Programme on Evidence Discussion Paper Series: No. 31. Geneva: World Health Organization; 2001.
10.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;9:335–51.CrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;9:335–51.CrossRef
13.
go back to reference Ebrahimi H, Aryan Z, Moghaddam SS, Bisignano C, Rezaei S, Pishgar F, et al. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the global burden of Disease Study 2019. The Lancet Respiratory Medicine. 2021;9(9):1030–49.CrossRef Ebrahimi H, Aryan Z, Moghaddam SS, Bisignano C, Rezaei S, Pishgar F, et al. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the global burden of Disease Study 2019. The Lancet Respiratory Medicine. 2021;9(9):1030–49.CrossRef
15.
go back to reference Ong SK, Lai DTCL, Wong JYY, Si-Ramlee KA, Razak LA, Kassim N, et al. Cross-sectional STEPwise approach to surveillance (STEPS) population survey of noncommunicable diseases (NCD) and risk factors in Brunei Darussalam 2016. Asia Pac J Public Health. 2017;29(8):635–48.CrossRefPubMed Ong SK, Lai DTCL, Wong JYY, Si-Ramlee KA, Razak LA, Kassim N, et al. Cross-sectional STEPwise approach to surveillance (STEPS) population survey of noncommunicable diseases (NCD) and risk factors in Brunei Darussalam 2016. Asia Pac J Public Health. 2017;29(8):635–48.CrossRefPubMed
17.
go back to reference Veetil SK, Lim KG, Chaiyakunapruk N, Ching SM, Hassan MRA. Colorectal cancer in Malaysia: its burden and implications for a multiethnic country. Asian J Surg. 2016;40:481–9.CrossRef Veetil SK, Lim KG, Chaiyakunapruk N, Ching SM, Hassan MRA. Colorectal cancer in Malaysia: its burden and implications for a multiethnic country. Asian J Surg. 2016;40:481–9.CrossRef
18.
go back to reference Sharma R, Abbasi-Kangevari M, Abd-Rabu R, Abidi H, Abu-Gharbieh E, Acuna JM, et al. Global, Regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627–47.CrossRef Sharma R, Abbasi-Kangevari M, Abd-Rabu R, Abidi H, Abu-Gharbieh E, Acuna JM, et al. Global, Regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(7):627–47.CrossRef
19.
go back to reference Leong E, Ong SK, Madli F, Tan A, Lai D, Basir N, et al. Survival rates and associated factors of colorectal cancer patients in Brunei Darussalam. Asian Pac J Cancer Prev. 2020;21(1):259–65.CrossRefPubMedPubMedCentral Leong E, Ong SK, Madli F, Tan A, Lai D, Basir N, et al. Survival rates and associated factors of colorectal cancer patients in Brunei Darussalam. Asian Pac J Cancer Prev. 2020;21(1):259–65.CrossRefPubMedPubMedCentral
20.
go back to reference Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast cancer (Dove Medical Press). 2019;11:151–64.PubMed Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast cancer (Dove Medical Press). 2019;11:151–64.PubMed
21.
go back to reference Hayes J, Richardson A, Frampton. Population attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women. Intern Med J. 2013;43:1198–204.CrossRefPubMed Hayes J, Richardson A, Frampton. Population attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women. Intern Med J. 2013;43:1198–204.CrossRefPubMed
22.
go back to reference Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of Disease Study 2017. J Hematol Oncol. 2019;12:140.CrossRefPubMedPubMedCentral Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of Disease Study 2017. J Hematol Oncol. 2019;12:140.CrossRefPubMedPubMedCentral
23.
go back to reference Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. THE BREAST. 2022;66:15–23.CrossRefPubMedPubMedCentral Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. THE BREAST. 2022;66:15–23.CrossRefPubMedPubMedCentral
24.
go back to reference Chaw LL, Lim STW, Yussof SRM. Human papillomavirus vaccine coverage among female students in Brunei Darussalam: results from the first 4 years of the national school-based vaccination programme. Heliyon. 2019;5(10):e02588.CrossRefPubMedPubMedCentral Chaw LL, Lim STW, Yussof SRM. Human papillomavirus vaccine coverage among female students in Brunei Darussalam: results from the first 4 years of the national school-based vaccination programme. Heliyon. 2019;5(10):e02588.CrossRefPubMedPubMedCentral
26.
go back to reference Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:354–61.CrossRefPubMed Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:354–61.CrossRefPubMed
27.
go back to reference Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):37–50.CrossRefPubMed Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):37–50.CrossRefPubMed
28.
go back to reference Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from: http://publications.iarc.fr/586. Accessed 19 May 2023. Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from: http://​publications.​iarc.​fr/​586. Accessed 19 May 2023.
29.
go back to reference Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006;66:1285–91.CrossRefPubMed Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006;66:1285–91.CrossRefPubMed
30.
go back to reference Chen C, Naidoo N, Yang Q, Hartman M, Verkooijen HM, Loy EY, et al. A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006. BMC Cancer. 2012;12:222.CrossRefPubMedPubMedCentral Chen C, Naidoo N, Yang Q, Hartman M, Verkooijen HM, Loy EY, et al. A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006. BMC Cancer. 2012;12:222.CrossRefPubMedPubMedCentral
31.
go back to reference Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMed Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMed
32.
go back to reference Zhao F, Xu Y, Yang K, Liu M, Wei D, Zhang Y. THADA gene polymorphism and prostate cancer risk: a meta-analysis. Oncol Res Treat. 2014;37:106–10.CrossRefPubMed Zhao F, Xu Y, Yang K, Liu M, Wei D, Zhang Y. THADA gene polymorphism and prostate cancer risk: a meta-analysis. Oncol Res Treat. 2014;37:106–10.CrossRefPubMed
34.
go back to reference Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer Inf. 2007;2:59–77. Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer Inf. 2007;2:59–77.
35.
go back to reference Ming C, Viassolo V, Probst-Hensch N, Chappuis PO, Dinov ID, Katapodi MC. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models. Breast Cancer Res. 2019;21:75.CrossRefPubMedPubMedCentral Ming C, Viassolo V, Probst-Hensch N, Chappuis PO, Dinov ID, Katapodi MC. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models. Breast Cancer Res. 2019;21:75.CrossRefPubMedPubMedCentral
Metadata
Title
Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020
Authors
Elvynna Leong
Sok King Ong
Khairil Azhar Si-Ramlee
Lin Naing
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10962-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine